Key Highlights

  • 9.76% was the gain in the traded price of Absci Corporation (NASDAQ:ABSI), which reached USD 8.32 on November 18, 2026 from a calculated prior close of USD 7.58, on Volume of 1.51M shares.
  • 173.7 in USD millions was cash, cash equivalents and marketable securities at September 30, 2026, which the company said funds operations into the second half of 2028.
  • 33.3 in USD millions was the third quarter 2026 net loss, or USD 0.19 per share, compared with a USD 28.7 million loss in the third quarter of 2025.
  • 13 weeks of interim proof-of-concept data for ABS-201 in pattern hair loss are expected in December 2026, with full 26-week data planned for early 2027.

What Moved Absci Corporation (NASDAQ:ABSI) in Trading on November 18, 2026 (+USD 0.74, +9.76%)

Absci Corporation traded at USD 8.32 in the November 18, 2026 session, a gain of 9.76%. The calculated prior close was USD 7.58, so the calculated move was +USD 0.74 per share. The stock opened 2.18% above the prior close, a calculated opening level of about USD 7.75, and then traded 7.42% above the open, so most of the advance came after the opening bell. Volume reached 1.51M shares. A corroborated market Capitalization was not available, so no Market Value is stated here.

The Rationale: Pipeline Anticipation Ahead of ABS-201 Data for Absci Corporation (NASDAQ:ABSI)

No company-specific catalyst dated November 18, 2026 was identified in published coverage. As general context, biotech shares often rally ahead of a scheduled clinical readout, and a rebound after a weak reaction to results can attract buyers. The most recent reported period is the third quarter of 2026, released on November 12, 2026. Partner program Revenue was USD 0.3 million, or USD 304 thousand, against USD 0.4 million a year earlier. Research and Development expense rose to USD 23.6 million from USD 19.2 million, and selling, general and administrative expense was USD 9.0 million against USD 8.4 million. Founder and Chief Executive Officer Sean McClain pointed to the first look at ABS-201 proof-of-concept data next month.

Valuation, Liquidity and Risks for Absci Corporation (NASDAQ:ABSI)

Absci reported a net loss of USD 33.3 million, or USD 0.19 per share, on weighted-average shares of 171,799,223 for the quarter. Cash, cash equivalents and marketable securities were USD 173.7 million at September 30, 2026, down from USD 201.1 million at June 30, 2026, a calculated decline of USD 27.4 million in one quarter. Revenue is minimal, so the valuation rests on pipeline prospects rather than earnings. A Phase 2 endometriosis trial is anticipated to begin in mid-2027. Risks include clinical outcomes for ABS-201, continuing losses, the need for future financing and dilution, and share price Volatility around data events.

Where Things Stand

Absci Corporation (NASDAQ:ABSI) advanced 9.76% to USD 8.32 on November 18, 2026, from a calculated prior close of USD 7.58, after opening 2.18% higher and adding a further 7.42% from the open. Volume was 1.51M shares. No catalyst for the session was identified in published coverage. The latest results, for the third quarter of 2026 and released November 12, 2026, showed revenue of USD 0.3 million, a net loss of USD 33.3 million and cash of USD 173.7 million. The company expects ABS-201 interim data in December 2026 and full data in early 2027. Share prices of clinical-stage companies can swing sharply around such milestones in either direction.